SPRINT ¿¬±¸´Â?
Systolic Blood Pressure Intervention Trial(SPRINT ¿¬±¸)Àº °íÇ÷¾Ð Ä¡·á¿¡¼ ½ÉÇ÷°üÁúȯÀÇ ¹ß»ý ¹× »ç¸ÁÀ» °¨¼Ò½ÃÅ°´Â ÃÖÀûÀÇ ¸ñÇ¥Ç÷¾ÐÀ» ã±â À§ÇÑ ¸î ¾ÈµÇ´Â ¿¬±¸µé Áß ÇÑ °¡Áö·Î °¡Àå ÃÖ±Ù¿¡ ¹ßÇ¥µÈ ¿¬±¸´Ù.1 ¿¬±¸¸¦ °£´ÜÈ÷ ¼Ò°³ÇÏ¸é ¹Ì±¹°ú Ǫ¿¡¸£Å丮ÄÚ¿¡¼ ÁøÇàµÆÀ¸¸ç, ´ç´¢º´°ú ³úÁ¹Áß È¯ÀÚ¸¦ Á¦¿ÜÇÑ °íÀ§Çè¿¡ ÇØ´çÇÏ´Â °íÇ÷¾Ð ȯÀÚ¸¦ ´ë»óÀ¸·Î Çß´Ù. ÁýÁßÄ¡·á±ºÀº ¸ñÇ¥Ç÷¾ÐÀ» 120mmHg ¹Ì¸¸À¸·Î, Ç¥ÁØÄ¡·á±ºÀº 140mmHg ¹Ì¸¸À¸·Î Ç÷¾Ð°ÇÏÁ¦ÀÇ Åõ¿©¸¦ Á¶ÀýÇØ µÎ Ä¡·á±º »çÀÌÀÇ ½É±Ù°æ»öÁõ, ±Þ¼º°üµ¿¸ÆÁõÈıº(ACS), ³úÁ¹Áß, ½ÉºÎÀüÁõ°ú ½ÉÇ÷°üÁúȯ¿¡ ÀÇÇÑ »ç¸ÁÀÇ ¹ß»ý Á¤µµ¸¦ ºñ±³Çß´Ù.
Ä¡·á 1³â° ÁýÁßÄ¡·á±ºÀÇ Æò±ÕÇ÷¾ÐÀº 121.4mmHgÀ̾úÀ¸¸ç, Ç¥ÁØÄ¡·á±ºÀÇ Æò±ÕÇ÷¾ÐÀº 136.2mmHgÀ̾ú´Ù. ÀÌ ¿¬±¸´Â ¾ç ±º °£ Ä¡·áÈ¿°úÀÇ Â÷ÀÌ°¡ ¶Ñ·ÇÇØ Á¶±â¿¡ Á¾·áµÆ´Ù. ÁýÁßÄ¡·á±ºÀº Ç¥ÁØÄ¡·á±º°ú ºñ±³ÇßÀ» ¶§ 1Â÷ º¹ÇÕ Æò°¡º¯¼ö(½É±Ù°æ»öÁõ + ACS + ³úÁ¹Áß + ½ÉºÎÀüÁõ + ½ÉÇ÷°üÁúȯ¿¡ ÀÇÇÑ »ç¸Á)ÀÇ ¹ß»ýÀÌ 25% ´õ ³·¾ÒÀ¸¸ç, Àüü»ç¸Á·üµµ 27% ´õ ³·¾Ò´Ù. ±×·¯³ª ÁýÁßÄ¡·á±º¿¡¼´Â Ç¥ÁØÄ¡·á±º°ú ºñ±³ÇØ Ä¡·á¿¡ µû¸¥ ÀúÇ÷¾Ð, ½Ç½Å, ÀüÇØÁú ÀÌ»ó, ±×¸®°í ±Þ¼º ½ÉºÎÀüÀÇ ÁßÁõ ÇÕº´ÁõÀÌ ´õ ¸¹ÀÌ ¹ß»ýÇß´Ù.
SPRINT ¿¬±¸°¡ °íÇ÷¾Ð Ä¡·á¿¡ ¹ÌÄ£ ¿µÇâ
ÀÌ ¿¬±¸°á°úÀÇ ¹ßÇ¥·Î °íÇ÷¾Ð ȯÀÚ¿¡¼ ¼öÃà±âÇ÷¾Ð °ÇϸñÇ¥¸¦ 120mmHg±îÁö ³·Ãç¾ß ÇÑ´Ù´Â ÁÖÀå°ú ÇÔ²² ¹Ì±¹½ÉÀåÇÐȸ¿Í ¹Ì±¹°íÇ÷¾ÐÇÐȸ´Â 2017³â °íÇ÷¾Ð Áø·áÁöħ¿¡¼ °íÇ÷¾Ð Áø´Ü±âÁØÀ» ¼öÃà±âÇ÷¾Ð 130mmHg ÀÌ»ó, È®Àå±âÇ÷¾Ð 80mmHg ÀÌ»óÀ¸·Î Çß´Ù.2 ±×¸®°í Á¤»ó±âÁØÀ» ¼öÃà±âÇ÷¾Ð 120mmHg ¹Ì¸¸, È®Àå±âÇ÷¾Ð 80mmHg ¹Ì¸¸À¸·Î ¼³Á¤Çß´Ù. ±×·¯³ª ÀÌ ±âÁØÀ» Àû¿ëÇÏ¸é °íÇ÷¾ÐÀÇ À¯º´·üÀÌ 50%¿¡ ±ÙÁ¢ÇÏ°ÔµÅ3 °úµµÇÑ °íÇ÷¾Ð Ä¡·á¿¡ ´ëÇÑ ¿ì·Á°¡ ÀÖÀ¸¸ç, »çȸÀûÀÎ ¹®Á¦¿¡ ´ëÇÑ °í·Áµµ ÇÊ¿äÇÏ´Ù.
ÀÌÀü°ú´Â ´Ù¸¥ Ç÷¾ÐÃøÁ¤ ¹æ¹ý
ÀÌ ¿¬±¸°á°ú°¡ ¹ßÇ¥µÇ°í ¼ö°³¿ù ÈÄ »õ·Î¿î ³íÀïÀÌ ½ÃÀ۵ƴÙ. SPRINT ¿¬±¸¿¡¼ »ç¿ëÇÑ Ç÷¾ÐÃøÁ¤ ¹æ¹ýÀÌ ÀÌÀüÀÇ ¿¬±¸¿¡¼ »ç¿ëµÇ´Â ¹æ¹ý°ú ´Ù¸£¸ç, Áø·áÇöÀå¿¡¼ ÃøÁ¤ÇÏ´Â ¹æ¹ý°ú ´Ù¸£´Ù´Â °ÍÀÌ ¾Ë·ÁÁ³´Ù.4,5 SPRINT ¿¬±¸¿¡¼´Â Áøµ¿¹ýÀ» ä¿ëÇÑ ÀÚµ¿Ç÷¾Ð°è¸¦ »ç¿ëÇßÁö¸¸ ¿¬±¸ÀÚ(ÀÇ»ç, °£È£»ç ¶Ç´Â º¸°Ç°ü°èÀÚ)°¡ Ç÷¾ÐÀ» ÃøÁ¤ÇÏÁö ¾Ê°í ȯÀÚ°¡ Á¶¿ëÇÑ ¹æ¿¡¼ È¥ÀÚ¼ ¾ÈÁ¤À» ÃëÇÏ°í ȯÀÚ°¡ Ç÷¾ÐÃøÁ¤ ½ÃÀÛ¹öÆ°À» ´©¸£¸é Ç÷¾ÐÀÌ ÀÚµ¿À¸·Î 3ȸ ÃøÁ¤µÇ´Â ¹æ¹ýÀ¸·Î Ç÷¾ÐÀ» ÃøÁ¤Çß´Ù(unattented automatic office BP, AOBP).
ij³ª´Ù¿¡¼´Â ¸¹Àº ¿¬±¸¸¦ ÅëÇØ Áø·áÁöħ¿¡¼ Ç¥ÁØ ÃøÁ¤¹æ¹ýÀ¸·Î ±Ç°íÇÏ°í ÀÖ´Â Ç÷¾ÐÃøÁ¤ ¹æ¹ýÀÌ´Ù.6,7 ÀÌ ¹æ¹ýÀÌ ¹éÀÇÈ¿°ú¸¦ ÃÖ¼ÒÈÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀÌÁö¸¸, ÀüÅëÀûÀ¸·Î ÀÇ»ç ¶Ç´Â °£È£»ç°¡ Á÷Á¢ ÃøÁ¤ÇÏ´Â Ç÷¾Ðº¸´Ù 10mmHg Á¤µµ ³·°Ô ÃøÁ¤µÈ´Ù. ÀÌ Áß¿äÇÑ Â÷ÀÌ´Â SPRINT ¿¬±¸°á°ú¿¡¼µµ º¸¿©Áø´Ù. ÀϹÝÀûÀ¸·Î 24½Ã°£ È°µ¿Ç÷¾ÐÀº Áø·á½Ç ÃøÁ¤Ç÷¾Ðº¸´Ù ³·°Ô ÃøÁ¤µÇÁö¸¸ SPRINT ¿¬±¸¿¡¼´Â Áø·á½Ç ÃøÁ¤Ç÷¾Ð°ú 24½Ã°£ È°µ¿Ç÷¾ÐÀÌ ºñ½ÁÇÑ °ªÀ¸·Î ÃøÁ¤µÅ8 SPRINT ¿¬±¸¿¡¼ »ç¿ëÇÑ ¹æ¹ýÀ¸·Î ÃøÁ¤µÈ Ç÷¾ÐÀÌ ÀüÅëÀûÀÎ ¹æ¹ýÀ¸·Î ÃøÁ¤µÈ Ç÷¾Ð°ú ´Ù¸£´Ù´Â °ÍÀ» °£Á¢ÀûÀ¸·Î º¸¿©ÁÖ°í ÀÖ´Ù.
±×·¯¹Ç·Î ÀÌÀüÀÇ ¿¬±¸°á°ú¸¦ Åä´ë·Î Á¤ÇØÁø °íÇ÷¾Ð Áø´Ü±âÁØ 140/90mmHg¸¦ SPRINT ¿¬±¸°á°ú¸¦ ¹Ý¿µÇØ ¼²ºÎ¸£°Ô 130/80mmHg·Î ³·Ãâ ¼ö´Â ¾ø¾î¼ ´ëÇÑ°íÇ÷¾ÐÇÐȸ¿Í À¯·´½ÉÀåÇÐȸ·°íÇ÷¾ÐÇÐȸ´Â °íÇ÷¾Ð Áø´Ü±âÁØÀ» 140/90mmHg·Î À¯ÁöÇß´Ù.9 ±×·¯³ª °íÇ÷¾ÐÀÇ Ç÷¾Ð°ÇÏ ¸ñÇ¥¸¦ ±âÁ¸ÀÇ 140/90mmHg ¹Ì¸¸¿¡¼ 130/80mmHg ÀÌÇÏ·Î ÇÏÇâ Á¶Á¤Çß´Ù. ¼öÃà±âÇ÷¾ÐÀ» 130mmHg ÀÌÇÏ·Î ÇÏÇâ Á¶Á¤ÇÑ ÀÌÀ¯´Â SPRINT ¿¬±¸¿¡¼ µµ´ÞÇÑ Ç÷¾Ð¿¡ ÀüÅëÀûÀÎ Ç÷¾ÐÃøÁ¤ ¹æ¹ýÀ» °í·ÁÇØ 10mmHg¸¦ ´õÇϸé 130mmHg Á¤µµ¿¡ µµ´ÞÇÑ °ÍÀ¸·Î ¿¹»óÇÏ°í ¶ÇÇÑ ¿©·¯ ¸ÞŸºÐ¼®ÀÇ °á°ú¸¦ ¹Ý¿µÇØ ÇÏÇâ Á¶Á¤Çß´Ù.
±×·¯³ª ÇöÀç±îÁö SPRINT ¿¬±¸¸¦ Á¦¿ÜÇÏ°í´Â Ãß°¡ÀûÀÎ ±Ù°Å°¡ ºÎÁ·ÇÏ°í, J-curveÀÇ À§Ç輺ÀÌ ÀÖ¾î ¼öÃà±âÇ÷¾ÐÀ» 120mmHg ¹Ì¸¸À¸·Î Á¶ÀýÇÏ´Â °ÍÀº ±Ç°íÇÏÁö ¾Ê°í ÀÖ´Ù.
SPRINT ¿¬±¸ÀÇ ¶Ç ´Ù¸¥ Á߿伺
ºñ·Ï Ç÷¾ÐÃøÁ¤ ¹æ¹ýÀÇ Â÷ÀÌ·Î SPRINT ¿¬±¸°á°ú¸¦ ±×´ë·Î Áø·áÁöħ¿¡ ¹Ý¿µÇϱâ´Â ¾î·ÆÁö¸¸ ÀÌ ¿¬±¸´Â Ç÷¾ÐÃøÁ¤ÀÇ ¹æ¹ýÀÌ ¾ó¸¶³ª Å« ¿µÇâÀ» ¹ÌÄ¡´Â Áö¸¦ º¸¿©Áá´Ù. ¾Õ¿¡¼ ¸»ÇÑ ¹Ù¿Í °°ÀÌ AOBP´Â Ç÷¾ÐÃøÁ¤ ½Ã ¾à 30% Á¤µµÀÇ È¯ÀÚ¿¡¼ ³ªÅ¸³ª´Â ¹éÀÇÈ¿°ú¸¦ ÃÖ¼ÒÈÇÒ ¼ö ÀÖ´Â °¡Àå Á¤È®ÇÑ Áø·á½Ç Ç÷¾ÐÃøÁ¤ ¹æ¹ýÀ¸·Î Æò°¡µÇ°í ÀÖ´Ù. ±×·¯³ª ÀÌ ¹æ¹ýÀ» ´çÀå ¿ì¸®ÀÇ Áø·áÇö½Ç¿¡ Àû¿ëÇϱ⿡´Â ´ÙÀ½°ú °°Àº ¹®Á¦Á¡ÀÌ ÀÖ´Ù. (1)ȯÀÚ°¡ È¥ÀÚ¼ Á¶¿ëÇÑ È¯°æ¿¡ ÀÖÀ¸¸ç ½º½º·Î Ç÷¾ÐÀ» ÃøÁ¤ÇÒ ¼ö Àִ ȯ°æ°ú ÀÌ·± ±â´ÉÀ» °¡Áö°í ÀÖ´Â ÀÚµ¿Ç÷¾Ð°è¸¦ ±¸ºñÇØ¾ß ÇÑ´Ù. ÇÏÁö¸¸ ÀÌ·± ȯ°æÀÇ ±¸¼º¿¡´Â °ø°£°ú ºñ¿ëÀÌ ÇÊ¿äÇØ ½±Áö´Â ¾ÊÀº ¹æ¹ýÀÌ´Ù.
(2)±×¸®°í ´õ¿í Áß¿äÇÑ °ÍÀº ÀÌ ¹æ¹ýÀ¸·Î ÃøÁ¤ÇÑ Ç÷¾ÐÀº ÀüÅëÀûÀÎ ¹æ¹ýÀ¸·Î ÃøÁ¤ÇÑ Ç÷¾Ð°ú Â÷ÀÌ°¡ ÀÖ¾î ÃøÁ¤µÈ Ç÷¾ÐÀ» ÀüÅëÀûÀÎ Ç÷¾ÐÀÇ ¼öÁØÀ¸·Î Æò°¡Çϱâ´Â ¾î·Æ´Ù´Â Á¡ÀÌ´Ù. ¿¹¸¦ µé¸é ÃøÁ¤ÇÑ Ç÷¾ÐÀÌ 136mmHgÀ̸é ÀüÅëÀûÀÎ Ç÷¾Ð±âÁØÀ¸·Î º¸¸é °íÇ÷¾ÐÀ¸·Î Áø´ÜÀÌ µÇÁö ¾ÊÁö¸¸ AOBP·Î ÃøÁ¤Çß´Ù¸é °íÇ÷¾ÐÀ¸·Î Áø´ÜÇÒ ¼öµµ ÀÖ´Ù. ÇöÀç±îÁö ÀÌ ¹æ¹ý¿¡ ÀÇÇÑ °íÇ÷¾Ð Áø´Ü±âÁØ¿¡ ´ëÇÑ ¸íÈ®ÇÏ°í °øÅëµÈ ±âÁØÀÌ ¾øÁö¸¸ ij³ª´Ù °íÇ÷¾Ð Áø·áÁöħ¿¡ ±Ù°ÅÇÏ¸é °íÇ÷¾ÐÀ¸·Î Áø´ÜµÈ´Ù.7 ±×·¯³ª AOBP´Â ´õ ¸¹Àº ¿¬±¸¸¦ ÅëÇØ Áø·áÇö½Ç¿¡ Àû¿ëÀÌ °¡´ÉÇÑ ¹æ¹ýÀ» ã¾Æ³»°í, ÀÌ ¹æ¹ýÀ» ÀÌ¿ëÇÑ °íÇ÷¾ÐÀÇ Áø´Ü ¹× Ä¡·á±âÁØÀÌ ¸¶·ÃµÈ´Ù¸é º¸Æí鵃 °¡´É¼ºµµ ÃæºÐÈ÷ ÀÖ´Ù.
¿ø³»·Áø·á½Ç Ç÷¾ÐÃøÁ¤¹ýÀÇ ÇöÀç¿Í ¹Ì·¡
SPRINT ¿¬±¸´Â ¿ì¸®³ª¶óÀÇ Ç÷¾ÐÃøÁ¤ ¹æ¹ý ÇöÀç¿Í ¹Ì·¡¿Í °ü·ÃÇØ Áß¿äÇÑ Àǹ̸¦ °¡Áö°í ÀÖ´Ù. ÇöÀç ¿ì¸®³ª¶ó¿¡¼´Â ÀüÅëÀûÀ¸·Î ¼öÀºÇ÷¾Ð°è¸¦ »ç¿ëÇÑ Ã»Áø¹ýÀÌ Áø·á½Ç¿¡¼ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖÁö¸¸ Áøµ¿¹ýÀ» ä¿ëÇÑ ÀüÀÚ½Ä Ç÷¾Ð°èµµ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ´Ù.
°ú°Å 1905³â Korotkoff¿¡ ÀÇÇØ Ç÷¾ÐÃøÁ¤ ¹æ¹ýÀ¸·Î ûÁø¹ýÀÌ Á¦¾ÈµÆÀ¸¸ç, ÀÌ ¹æ¹ýÀÌ Áøµ¿¹ýº¸´Ù ¿ì¼öÇØ 100³â ÀÌ»ó Ç¥ÁØ ÃøÁ¤¹æ¹ýÀ¸·Î »ç¿ëµÅ ¿Ô´Ù. ûÁø¹ýÀº Áøµ¿¹ý¿¡ ºñÇØ ¿ì¼öÇÔ¿¡µµ º¹ÀâÇϰųª ½Ã²ô·¯¿î Áø·áȯ°æ°ú ÃøÁ¤ÀÚÀÇ ÈÆ·Ã Á¤µµ¿¡ ¸¹Àº ¿µÇâÀ» ¹Þ´Â ¹®Á¦Á¡(Áï ÃøÁ¤ÀÚ°¡ ¾î¶»°Ô ÃøÁ¤Çϴ°¡¿¡ ¿µÇâÀ» ¸¹ÀÌ ¹Þ´Â´Ù)À» °¡Áö°í ÀÖ´Ù. ±×¸®°í »ç¿ëÇÏ´Â ¼öÀºÇ÷¾Ð°è ¶Ç´Â ¾Æ³×·ÎÀ̵åÇ÷¾Ð°èÀÇ À¯Áö º¸¼ö¿¡ µû¶ó¼ Á¤È®¼º¿¡ ¿µÇâÀ» ¹Þ´Â´Ù. 2013³â Ç¥ÁØ¿¬±¸¼ÒÀÇ Á¶»ç¿¡ ÀÇÇϸé Áø·á¿¡¼ »ç¿ëÇÏ°í ÀÖ´Â Ç÷¾Ð°è Áß¿¡¼ ¾Æ³×·ÎÀ̵åÇ÷¾Ð°èÀÇ 18.2%(187´ëÁß 34´ë), ¼öÀºÇ÷¾Ð°èÀÇ 7.3%(164´ë Áß 12´ë)°¡ ¿ÀÂ÷Çѵµ(±3mmHg)¸¦ ³Ñ¾î¼± °ÍÀ¸·Î Á¶»çµÆ´Ù.
¿Ü±¹ÀÇ ¸¹Àº ³ª¶ó¿¡¼´Â ÀÌ¹Ì ¿À·¡Àü¿¡ »ç¿ëÀÌ Áß´ÜµÈ ¼öÀºÇ÷¾Ð°è°¡ ¿ì¸®³ª¶ó¿¡¼µµ 2020³âºÎÅÍ »ç¿ëÀÌ ÁߴܵǹǷΠÀÚµ¿ ¶Ç´Â ¹ÝÀÚµ¿ÀÇ ÀüÀÚÇ÷¾Ð°è¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁø »óȲÀ̸ç, ¸¹Àº Ç÷¾Ð°è°¡ ÀÚµ¿ ¶Ç´Â ¹ÝÀÚµ¿ÀÇ ÀüÀÚÇ÷¾Ð°è·Î ´ëüµÉ °ÍÀ¸·Î ¿¹»óµÈ´Ù. ÃÖ±Ù ±â¼úÀÇ ¹ßÀüÀ¸·Î Áøµ¿¹ýÀ» ä¿ëÇÑ ¹ÝÀÚµ¿ ¶Ç´Â ÀÚµ¿Ç÷¾Ð°èÀÇ Á¤È®¼ºÀÌ Çâ»óµÅ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖÀ¸¸ç, ÃøÁ¤µÈ Ç÷¾Ð°ªÀÇ Á¤È®¼º¿¡ ´ëÇÑ ³í¶õÀÌ ÀÖÁö¸¸10 ÃøÁ¤ÀÚ °£ÀÇ ¿ÀÂ÷¸¦ ÁÙÀÏ ¼ö ÀÖ´Â ÀåÁ¡À» °¡Áö°í ÀÖ¾î ´ë±Ô¸ð ´Ù±â°ü Àӻ󿬱¸¿¡ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ´Ù.
°íÇ÷¾ÐÀÇ ´ëÇ¥ ¿¬±¸µéÀÎ HOT, ADVANCE, HOPE-3, ASCOT, ACCORD, SP3, TROPHY, ONTARGET, TRANSCEND¿¡¼ »ç¿ëµÆÀ¸¸ç, ¿ì¸®³ª¶óÀÇ ¸¹Àº Ç÷¾Ð°ÇÏÁ¦ÀÇ Çã°¡¿ë ÀÓ»ó½ÃÇè ¹× ¸¹Àº °íÇ÷¾Ð Àӻ󿬱¸¿¡¼ »ç¿ëµÆ´Ù. ÀÌµé ¿¬±¸´Â Áøµ¿¹ýÀ» ä¿ëÇÑ ¹ÝÀÚµ¿ ¶Ç´Â ÀÚµ¿Ç÷¾Ð°è¸¦ »ç¿ëÇßÀ¸¸ç, À̵é Ç÷¾Ð°è´Â Ç÷¾ÐÃøÁ¤ÀÇ Á¤È®¼º¿¡ ´ëÇØ ¼öÀºÇ÷¾Ð°è¸¦ »ç¿ëÇÑ Ã»Áø¹ýÀ» ±â¹ÝÀ¸·Î ½Å·Ú¼º Å×½ºÆ®¸¦ Åë°úÇß´Ù.
Áøµ¿¹ýÀ» »ç¿ëÇÏ´Â ÀÚµ¿ ¶Ç´Â ¹ÝÀÚµ¿Ç÷¾Ð°è´Â ÃøÁ¤ÀÇ Á¤È®¼º¿¡ ´ëÇÑ ½Å·Ú¼º Å×½ºÆ®¸¦ Åë°úÇÑ ±â±â¸¦ »ç¿ëÇÏ´Â °ÍÀ» ÃßõÇϸç,11 Å×½ºÆ® Åë°ú ¿©ºÎ´Â À¯·´ÀÇ dabl® Educational Trust¿¡¼ È®ÀÎÇϵµ·Ï ÃßõµÇ±âµµ ÇÏÁö¸¸ ÀÌ È¨ÆäÀÌÁö´Â À¯·´¿¡¼ »ç¿ëµÇ´Â ±â±â¿¡ ´ëÇÑ ½Å·Ú¼º Å×½ºÆ® Åë°ú ¿©ºÎ¸¦ °Ô½ÃÇÏ°í ÀÖ¾î Çѱ¹¿¡¼ »ç¿ëµÇ´Â Ç÷¾Ð°è´Â ¾ø´Â °æ¿ì°¡ ÀÚÁÖ ÀÖ´Ù. ¶ÇÇÑ ³ª¶ó¸¶´Ù ±Ô°Ý¿¡ µû¶ó¼ ¼·Î ´Ù¸¥ ¸ðµ¨¸íÀ¸·Î »ç¿ëµÇ±âµµ ÇÏ°í, µ¿ÀÏ ¸ðµ¨¸íÀ̾ ´Ù¸¥ Ç÷¾Ð°èÀÎ °æ¿ì°¡ ÀÖÀ¸¹Ç·Î ¿ì¸®³ª¶ó¿¡¼´Â Á¦Á¶»ç¿¡ ¹®ÀÇÇØ È®ÀÎÇØ¾ß ÇÑ´Ù.
¸¶Áö¸·À¸·Î Ç÷¾ÐÀÇ ÃøÁ¤¿¡¼ ûÁø¹ý ¶Ç´Â Áøµ¿¹ý, ¼öÀºÇ÷¾Ð°è, ¾Æ³×·ÎÀ̵åÇ÷¾Ð°è, ¶Ç´Â ÀüÀÚÇ÷¾Ð°è¿¡¼ ¾î´À ¹æ¹ýÀÌ ¿ì¼öÇÏ´Ù´Â °Íº¸´Ùµµ °¡Àå Áß¿äÇÑ °ÍÀº °¡´ÉÇÑ Áø·áÁöħ µî¿¡¼ Á¦½ÃÇÏ°í ÀÖ´Â ¹æ¹ý´ë·Î ÃøÁ¤ÇØ¾ß ÇÑ´Ù. Á¶¿ëÇÑ È¯°æ¿¡¼ ÃæºÐÇÑ ÈÞ½ÄÀ» ÃëÇÏ°í ÃøÁ¤ Àü¿¡ Ç÷¾Ð¿¡ ¿µÇâÀ» ÁÖ´Â Á¶°ÇÀ» ¹èÁ¦ÇÏ°í ÃøÁ¤À» Çϵµ·Ï ÇØ¾ß Çϸç, ÇÑ ¹ø ÃøÁ¤À¸·Î Æò°¡ÇÏÁö ¸»°í ¿©·¯ ¹ø ÃøÁ¤ÇÏ°í ¿©·¯ ³¯¿¡ °ÉÃļ ÃøÁ¤ÇÏ¿© ȯÀÚÀÇ Ç÷¾Ð¼öÁØÀ» Æò°¡Çϵµ·Ï ÇØ¾ß ÇÑ´Ù.
References
1. Group SR, Wright JT, Jr., Williamson JD, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. The New England journal of medicine. 2015;373(22):2103-2116.
2. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115.
3. Lee JH, Kim SH, Kang SH, et al. Blood Pressure Control and Cardiovascular Outcomes: Real-world Implications of the 2017 ACC/AHA Hypertension Guideline. Scientific reports. 2018;8(1):13155.
4. Schiffrin EL, Calhoun DA, Flack JM. SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price. American journal of hypertension. 2016;29(1):2-4.
5. Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials. Hypertension. 2016;67(5):808-812.
6. Myers MG. Automated Office Blood Pressure Measurement. Korean circulation journal. 2018;48(4):241-250.
7. Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. The Canadian journal of cardiology. 2018;34(5):506-525.
8. Drawz PE, Pajewski NM, Bates JT, et al. Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. Hypertension. 2017;69(1):42-50.
9. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of hypertension. 2018;36(10):1953-2041.
10. Lim YH, Choi SY, Oh KW, et al. Comparison between an automated device and a manual mercury sphygmomanometer in an epidemiological survey of hypertension prevalence. American journal of hypertension. 2014;27(4):537-545.
11. Stergiou GS, Alpert B, Mieke S, et al. A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. Journal of hypertension. 2018;36(3):472-478.
THE MOST webmaster@mostonline.co.kr
<ÀúÀÛ±ÇÀÚ © THE MOST, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>